Contraception
📧 Sign up to get email alerts when something new happens for Contraception.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA [Phase 4]
Phase 4 trial evaluating the effectiveness of orally dosed emergency contraception in obese women.
-
CLINICAL_TRIALS trial_result · 2024-02-02Clinical Trial Update: Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™ [Phase 4]
Phase 4 clinical trial investigating the effects of a progestin on frequent and/or prolonged bleeding associated with Nexplanon (a contracep…
-
FDA approval · 2024-02-01FDA Approved: TRI-ESTARYLLA — Supplemental Application (Xiromed, LLC.)
FDA approved a supplemental application for Tri-Estarylla (norgestimate and ethinyl estradiol) from Xiromed, LLC., supporting an additional …
-
FDA approval · 2024-01-05FDA Approved: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for norethindrone acetate and ethinyl estradiol tablets (oral contraceptive) developed by Mylan Phar…
-
FDA approval · 2024-01-03FDA Approved: MARLISSA — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves a supplemental application for MARLISSA (levonorgestrel and ethinyl estradiol) submitted by Glenmark Pharmaceuticals Inc., USA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-14Clinical Trial Update: A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles [Phase 3]
A multicenter Phase 3 non-comparative trial evaluating the contraceptive efficacy, safety, and tolerability of LPRI-424 over 13 cycles has b…
-
FDA approval · 2023-10-24FDA Approved: NIKKI — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals’ supplemental application for NIKKI, a combined oral contraceptive containing drospirenone and ethinyl es…
-
FDA approval · 2023-10-24FDA Approved: VESTURA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for VESTURA (drospirenone and ethinyl estradiol) from Teva, updating labeling to support its use…
-
FDA approval · 2023-10-18FDA Approved: ESTRADIOL AND NORETHINDRONE ACETATE — Supplemental Application (Ingenus Pharmaceuticals, LLC)
The FDA approved a supplemental application for Estradiol and Norethindrone Acetate from Ingenus Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: A Multicentre, Prospective, Open-label, Non-comparative Study [Phase 4]
A multicentre, prospective open-label Phase 4 trial in contraception is reported, status unknown.
-
FDA approval · 2023-09-28FDA Approved: DROSPIRENONE AND ETHINYL ESTRADIOL — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for a generic drospirenone/ethinyl estradiol contraceptive from Glenmark Pharmaceuticals Inc., USA.
-
FDA approval · 2023-09-25FDA Approved: JUNEL 21 DAY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for JUNEL 21 DAY (norethindrone acetate and ethinyl estradiol) from Teva Pharmaceuticals USA, in…
-
FDA approval · 2023-09-25FDA Approved: JUNEL FE 28 DAY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for JUNEL FE 28 DAY (norethindrone acetate and ethinyl estradiol and ferrous fumarate) from Teva Pha…
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy [Phase 2]
Phase 2 pharmacokinetic study evaluating levonorgestrel implant with antiretroviral therapy in HIV and contraception contexts; completed.
-
FDA approval · 2023-08-16FDA Approved: DROSPIRENONE AND ETHINYL ESTRADIOL — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Camber Pharmaceuticals' generic drospirenone/ethinyl estradiol, making this combined oral contra…
-
FDA approval · 2023-08-09FDA Approved: BLISOVI FE 1.5/30 — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' BLISOVI FE 1.5/30 through a supplemental approval, adding a 1.5 mg norethindrone/30 mcg ethinyl estradio…
-
CLINICAL_TRIALS research · 2023-08-03Clinical Trial Update: Essure Transvaginal Ultrasound (TVU) Study [Phase 4]
Clinical trial update for Essure transvaginal ultrasound study (Phase 4) completed under Bayer.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV [Phase 4]
A Phase 4 clinical trial is investigating the interaction between two long-acting reversible contraception methods and dolutegravir for HIV …
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: SexHealth Mobile: Integrating a Mobile Clinic and a Point-of-care Contraception Counseling and Access [NA]
Completed clinical trial evaluating a mobile clinic and point-of-care contraception counseling and access.
-
FDA approval · 2023-07-17FDA Approved: LARIN FE 1.5/30 — Supplemental Application (Northstar Rx LLC)
FDA approved a supplemental application for LARIN FE 1.5/30, a combined oral contraceptive containing norethindrone acetate/ethinyl estradio…
-
FDA approval · 2023-07-14FDA Approved: TARINA 24 FE — Supplemental Application (Afaxys Pharma, LLC)
FDA approved a supplemental application for Tarina 24 FE, a combined oral contraceptive containing norethindrone acetate, ethinyl estradiol,…
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction [Phase 4]
Phase 4 clinical trial exploring potential drug–drug interaction between cannabidiol and oral contraceptive pills.
-
FDA approval · 2023-06-30FDA Approved: ETYQA — Original Application (Aurobindo Pharma Limited)
FDA approved ETYQA, a generic estradiol and norethindrone acetate combination tablet from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Evaluation of Polyurethane Male Condoms [NA]
Completed clinical trial evaluating polyurethane male condoms for contraception and prevention of sexually transmitted infections; results p…
-
FDA approval · 2023-06-22FDA Approved: MIBELAS 24 FE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin's supplemental application for MIBELAS 24 FE, a combination oral contraceptive containing norethindrone acetate, ethinyl …